课题基金 / 基金详情

IDENTIFICATION OF GENERIC SUPRESSORS OF PROTEINOPATHIES

IDENTIFICATION OF GENERIC SUPRESSORS OF PROTEINOPATHIES
蛋白质病通用抑制剂的鉴定
批准号:
MR/J006904/1
负责人:
David Rubinsztein
金额:
$51.91万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2011
资助国家:
英国
项目状态:
已结题
起止时间:
2011 至 --

项目摘要

项目成果

David Rubinsztein的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We aim to identify genes that reduce the toxicity of a wide range of different mutant proteins that cause neurodegeneration. We will identify such genes and pathways by performing a bioinformatics analysis of existing genetic screens for modifiers in lower organisms (from yeast to Drosophila), as well as targeted studies in all systems, including high confidence genome wide association study hits for Alzheimer's and Parkinson's disease and ALS. Using multiple data sources, we will identifyhallmark features of "generic modifiers" and use computational methods to identifynew modifiers, which will then be tested for efficacy in fruit fly models of different diseases, like Huntington's disease and forms of dementia. Novel modifiers showing efficacy in morethan one disease will be studied in cell models and fruit flies to identify mechanisms ofaction. The identification of such "generic" supressors and their mechanisms wouldcreate a list of high priority targets for consideration for therapeutic development and/ordetailed mechanistic analyses, as these would be acting on a range of diseases and areexpected to affect core processes.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1186/1755-8794-6-52
发表时间: 2013-11-14
期刊: BMC medical genomics
影响因子: 2.7
作者: [Na D, Rouf M, O'Kane CJ, Rubinsztein DC, Gsponer J]
通讯作者: Gsponer J
DOI: 10.1038/cdd.2014.151
发表时间: 2015-03
期刊: Cell death and differentiation
影响因子: 12.4
作者: []
通讯作者:
siRNA screen identifies QPCT as a druggable target for Huntington's disease.
siRNA 筛选将 QPCT 识别为亨廷顿病的药物靶点。
DOI: 10.17863/cam.17368
发表时间: 2015
期刊:
影响因子: --
作者: [Jimenez-Sanchez M]
通讯作者: Jimenez-Sanchez M
DOI: 10.1038/ncomms2212
发表时间: 2012
期刊: Nature communications
影响因子: 16.6
作者: []
通讯作者:
BBSRC Industrial CASE Partnership Grant
  • 批准号:
    BB/I532496/1
  • 项目类别:
    Training Grant
  • 资助金额:
    $9.59万
  • 财政年份:
    2010
  • 负责人:
    David Rubinsztein
  • 依托单位:
Modifiers of polyglutamine disease pathogenesis
  • 批准号:
    G0600194/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $347.59万
  • 财政年份:
    2007
  • 负责人:
    David Rubinsztein
  • 依托单位:
海外基金